Likewise, Giannicola and colleagues18 reported that positive autoantibodies (ANA, ENA, anti‐smooth muscle cell antigens), emerging within the first 30 days of ICI treatment, were associated with increased PFS and overall survival (OS) in NSCLC patients receiving Nivolumab therapy. This evidence concerns the gene BTG3 and non-small cell lung carcinoma.